1. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. (14th April 2018) Authors: Novello, S; Mazières, J; Oh, I -J; de Castro, J; Migliorino, M R; Helland, Å; Dziadziuszko, R; Griesinger, F; Kotb, A; Zeaiter, A; Cardona, A; Balas, B; Johannsdottir, H K; Das-Gupta, A; Wolf, J Journal: Annals of oncology Issue: Volume 29:Number 6(2018) Page Start: 1409 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. (12th September 2018) Authors: Gadgeel, S; Peters, S; Mok, T; Shaw, A T; Kim, D W; Ou, S I; Pérol, M; Wrona, A; Novello, S; Rosell, R; Zeaiter, A; Liu, T; Nüesch, E; Balas, B; Camidge, D R Journal: Annals of oncology Issue: Volume 29:Number 11(2018) Page Start: 2214 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P907Titration patterns and clinical characteristics of patients prescribed sacubitril/valsartan in the primary care and cardiology settings in Germany. (28th August 2018) Authors: Wachter, R; Balas, B; Klebs, S; Kap, E; Engelhard, J; Fonseca, A F; Schlienger, R; Dworak, M; Bruce Wirta, S Journal: European heart journal Issue: Volume 39(2018)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗